Senior Clinical Operations Contractor

Whats happening at Entrada Therapeutics Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44 45 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program VX-670 for myotonic dystrophy type 1 (DM1).

2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K. EU and U.S. By year-end 2026 we anticipate four clinical-stage programs in our DMD franchise (ENTRENTRENTRand ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670).

We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy dedicated team that likes to get things done and dramatically improve the lives of patients and their families.

You are excited about the opportunity to spearhead clinical trial activities and support the continued growth of our clinical operations function here at Entrada. You are well organized and like to share best practices in clinical operations. You enjoy a fast-paced environment and juggling competing priorities and are willing to jump in and help wherever it is needed. You follow up and follow through efficiently connecting problems with solutions. You work successfully in a team environment and have strong interpersonal skills in order to effectively build working relationships inside and outside of the company.

This individual will lead in the day-to-day operations planning set-up execution and closeout of assigned clinical trials. They will oversee the planning and management of the operational aspects including CRO and vendor oversight to achieve project milestones and clinical study timelines in alignment with company goals and in compliance with local ICH GCP and company policies and procedures.

• Lead and/or support study activities including vendor evaluation and selection country and site selection informed consent development and maintenance eCRF design and implementation protocols study plans and manuals IBs CSRs etc.
• Proactively identify and support resolution/escalation of trial conduct-related issues.
• Manage and lead cross-functional trial teams including collaborating with internal team members and external vendors for the planning and execution of clinical trials through closeout.
• Provide regular up-to-date trial information and regular updates on trial progress/performance to internal stakeholders (enrollment eligibility protocol deviations AE reporting etc.).
• Oversee clinical monitoring from site qualification to site closure visits to assure integrity of clinical data with respect to accuracy accountability and documentation through review of case report forms source documents and medical records.
• Oversee the review/cleaning and reconciliation of all clinical data including EDC PROs and 3rd party labs to support timely database lock and the accurate analysis of clinical data.

At Entrada our passion for science our devotion to patients and our values drives ourbehavior:

• Humanity - We genuinely care about patients and about one another.
• Tenacity - We are relentless and persistent in the pursuit of developing therapiesfor patients.
• Creativity - We are creative problem solvers.
• Collaboration - We are more than the sum of our parts.
• Curiosity - We have a growth mindset and push conventional thought and theory.

To thrive on our team you will need to come with:

• BA/BS degree with 7 years of combined experience supporting and independently managing clinical trial activities.
• Strong knowledge of ICH/GCP and regulatory requirements with a strong preference for experience with EU-CTR.
• Strong experience in the drug development process including trial design trial planning and management and CRO and vendor oversight.
• Excellent verbal and written communication skills.
• Proven ability to work effectively across functions.
• This is a long-term contract position with an expected 30-40 hours per week. It is a US based remote position with preference given to local New England based candidates. This role will require minimum monthly or quarterly travel to the Entrada Therapeutics Headquarters located in Boston MA. #LI-Remote #LI-JF1

Entrada Therapeutics is an equal opportunity employer. Qualified candidates will receive consideration for employment without regard to race color religion national origin gender sexual orientation gender identity or expression age mental or physical disability and genetic information marital status citizenship status military status protected veteran status or any other category protected by law.

Entrada does not accept unsolicited resumes from any source other than directly from candidates. For the protection of all parties involved in the recruiting process resumes will only be accepted from recruiters/agencies if a signed agreement is in place at the inception of the recruiting effort and authorized for a specified position. Unsolicited resumes sent to Entrada from recruiters/agencies do not constitute any type of relationship between the recruiter/agency and Entrada and do not obligate Entrada to pay fees if we hire from those resumes.

Entrada Therapeutics Inc. (the Entrada we us or our) respects your privacy and we want you to be familiar with how we collect use share or otherwise process your Personal Information. Please reference our privacy statement here to understand how and when your data is being used.